Navigation Links
Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
Date:5/26/2009

PRINCETON, N.J., May 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to host a conference call and live webcast at 4:00 p.m. Eastern Time on Tuesday, June 2, 2009. Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex will provide an update and recent highlights from Medarex's pipeline.

The webcast of the live event and archive can be accessed through the Investor Relations section of Medarex's website at www.medarex.com. To access the call live, please dial 1-877-874-1567 (U.S./Canada) or 1-719-325-4768 (international).

An archived telephonic replay of the conference call will be available until midnight Eastern Time on June 9, 2009. Access numbers for this replay are 1-888-203-1112 (U.S./Canada) or 1-719-457-0820 (international); the replay passcode is 4826956.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently approved for commercial sale, the subject of regulatory applications for marketing authorization, or in Phase 3 clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex Announces 2009 First Quarter Financial Results
2. Medarex to Host Business and Financial Update Conference Call on Thursday, April 30, 2009
3. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
4. Medarex to Present at the Needham Cancer Therapeutics Conference
5. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
6. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
7. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
8. Medarex to Present at the RBC Capital Markets Healthcare Conference
9. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
10. Medarex Announces 2008 Third Quarter Financial Results
11. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness ... targeting the needs of consumers who are incorporating medical marijuana into their wellness ... Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s two ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers ... perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). ... Institute. The event is free and open to the public, but registration is ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):